424 Capital exits Reverba in strategic sale
Reverba, a patient and healthcare professional engagement provider for life sciences companies, was acquired in a strategic transaction; terms were not disclosed.
- Target
- Reverba
- Buyer
- Undisclosed strategic buyer
- Seller
- 424 Capital
- Status
- Completed
424 Capital announced the successful exit of its investment in Reverba, which was acquired in a strategic transaction. The buyer and terms were not disclosed.
Reverba, formerly Health Perspectives Group, provides patient and healthcare professional engagement services to pharmaceutical and biotechnology companies across the drug-development and commercialization lifecycle. 424 Capital partnered with the company in 2021. During that period, Reverba acquired Six Degrees Medical, adding medical communications capabilities and an international presence.
Amit Nagdev, Partner at 424 Capital, said the firm worked with Reverba's leadership to strengthen the organization and expand its capabilities. Baird served as exclusive financial adviser to Reverba, and Whiteman Osterman & Hannah LLP served as legal counsel.
Background
- Business
- Patient and healthcare professional engagement provider to life sciences companies, formerly Health Perspectives Group
- Deal type
- Exit
- Advisers
- Baird financial adviser to Reverba
- Whiteman Osterman & Hannah LLP legal counsel to Reverba
Sources
- PR NewswireNov 19, 2026
Written by Buyout Desk from the sources above. Spotted an error? Email corrections@buyoutdesk.com.
Follow coverage. Copy a feed link into your feed reader.